Cencora, Inc.
Recent
price
P/E
ratio
div
yld
0.69%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cencora, Inc. (NYSE: COR) serves as a leading global pharmaceutical solutions organization that provides end-to-end pharmaceutical distribution, commercialization support, and related services to manufacturers, healthcare providers, pharmacies, hospitals, and health systems worldwide. Founded in 1871 and headquartered in Conshohocken, Pennsylvania, the company operates through U.S. Healthcare Solutions and International Healthcare Solutions segments; it distributes brand-name, specialty brand-name, generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment; offers wholesale and specialty distribution, pharmacy solutions, provider solutions, hospital and health system solutions, logistics and warehousing, drug research and clinical development support, commercialization support, and patient access and adherence programs; and serves acute care hospitals, independent and chain retail pharmacies, mail-order facilities, physicians, clinics, long-term care, assisted living centers, workers' compensation patients, and alternate site facilities across the United States, Canada, and other international markets. In recent developments, Cencora changed its name from AmerisourceBergen Corporation in August 2023; entered a definitive agreement in November 2024 to acquire Retina Consultants of America, a management services organization for retina specialists, for approximately $4.6 billion in cash plus up to $500 million in contingent consideration to expand its specialty capabilities and physician relationships; and announced in November 2025 a $1 billion investment through 2030 to strengthen its U.S. distribution network, including a new 530,000-square-foot national distribution center in Harrison, Ohio by spring 2027, expansions in Fontana, California and Dothan, Alabama with advanced automation and increased refrigerated capacity, and enhanced global cold chain logistics with a new third-party logistics facility planned in Italy in 2026.
Company News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)
Cencora to acquire American Oncology Network in $2.4 billion deal
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
IFP Advisors Inc Purchases 14,078 Shares of Cencora, Inc. $COR
Cencora, Inc. $COR Stake Increased by Frank Rimerman Advisors LLC
Cencora (NYSE:COR) and Option Care Health (NASDAQ:OPCH) Financial Contrast
AI Disruption May Benefit Cencora More Than Hims & Hers
23,420 Cencora, Inc. $COR Shares Bought by NorthCrest Asset Manangement LLC
Hims & Hers Health (NYSE:HIMS) vs. Cencora (NYSE:COR) Head to Head Review
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
Anthropic pushes for opt-out model for Australian content as ABC warns of ‘cannibalisation' of news
Cencora Elects Robert E. Sanchez to Its Board of Directors
Here's Why Cencora (COR) is a Strong Growth Stock
Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference
Here's Why Cencora (COR) is a Strong Value Stock
Corient Private Wealth LP Purchases 19,068 Shares of Cencora, Inc. $COR